| Abstract: |
| CAR-T cell immunotherapy involves the genetic reprogramming of T-lymphocytes to recognize and engage cancer cells, thereby triggering an anti-tumour immune response. While this treatment has been approved for hematological malignancies, its application to solid tumours presents significant new obstacles. These challenges include the heterogeneity of antigen expression, the presence of antigen-positive non-tumoural cells, immune inhibitory molecules, and the limited trafficking of CAR-T cells within the complex tumour microenvironment. In this talk, we explore a modification of the model introduced by Bodnar et al. (Nonlinear Dynamics, 2025).
The original model neglected the production of B-cells; here, we extend the framework by incorporating appropriate terms to account for their dynamics. The resulting system of two ordinary differential equations describes the interaction between CAR-T cells in the blood and B-cells, which in turn influences the dynamics of both tumour cells and CAR-T cells in the brain. We present stability analyses for the system under both constant and impulsive treatment regimens, accounting for the external influx of both CAR-T and B-cells. |
|